Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review

*Emmanuel Ifeanyi Obeagu¹ and Getrude Uzoma Obeagu²

Abstract

Pregnancy in women with sickle cell anemia (SCA) presents unique challenges, exacerbated by the hemolytic burden inherent in the condition. This review explores the hemolysis challenges faced by pregnant women with SCA, examining their implications for maternal and fetal health, complications such as vaso-occlusive crises and acute chest syndrome, and strategies for management and prevention. Physiological changes during pregnancy exacerbate hemolysis, leading to increased maternal morbidity and mortality, as well as adverse fetal outcomes such as growth restriction and preterm birth. Management strategies aim to optimize prenatal care, monitor maternal and fetal well-being, and minimize the impact of hemolysis on pregnancy outcomes. Hydroxyurea therapy may be considered, although its safety in pregnancy requires careful evaluation. Despite advances in care, pregnant women with SCA continue to face challenges related to hemolysis, highlighting the need for further research and tailored interventions to improve pregnancy outcomes in this vulnerable population.

Keywords: Hemolysis, Pregnant Women, Sickle Cell Anemia, Complications, Management

Introduction

Sickle cell anemia (SCA) represents a significant health concern globally, particularly among pregnant women, where the interplay of the condition's hemolytic nature and the physiological

¹Department of Medical Laboratory Science, Kampala International University, Uganda.

²School of Nursing Science, Kampala International University, Uganda.

^{*}Corresponding authour: Emmanuel Ifeanyi Obeagu, <u>Department of Medical Laboratory Science</u>, <u>Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID:</u> 0000-0002-4538-0161

changes of pregnancy poses unique challenges. SCA, an inherited hemoglobinopathy characterized by abnormal hemoglobin S (HbS), leads to chronic hemolysis, vaso-occlusive events, and multiorgan complications. Pregnancy exacerbates the hemolytic burden in women with SCA due to increased blood volume, hemodilution, and hypercoagulability, placing additional stress on already compromised erythrocytes. Pregnancy in women with SCA presents a delicate balance between the physiological demands of gestation and the pathological processes inherent in the condition. Hemolysis, a hallmark feature of SCA, is intensified during pregnancy, resulting in elevated maternal morbidity and mortality rates, as well as adverse fetal outcomes. Complications such as vaso-occlusive crises, acute chest syndrome, and alloimmunization further compound the challenges faced by pregnant women with SCA, necessitating vigilant monitoring and tailored management strategies.¹⁻²⁵

Understanding the pathophysiology of hemolysis in pregnancy is paramount for optimizing prenatal care and improving pregnancy outcomes in women with SCA. Physiological changes, such as increased erythropoiesis and altered hemorheology, contribute to the hemolytic process, exacerbating maternal anemia and increasing the risk of complications. Additionally, pregnancy-related factors such as preeclampsia and infection can exacerbate hemolysis, underscoring the multifactorial nature of the condition during gestation. Effective management of hemolysis during pregnancy in women with SCA requires a comprehensive approach that addresses both maternal and fetal health. Prenatal care should include regular monitoring of maternal hemoglobin levels, fetal growth, and placental function, as well as assessment of potential complications. Management strategies may encompass the use of hydroxyurea therapy to reduce hemolytic burden and prevent vaso-occlusive crises, although its safety in pregnancy remains a subject of debate and requires careful consideration. ²⁶⁻⁴⁵

Pathophysiology of Hemolysis in Pregnancy

The physiological changes of pregnancy interact intricately with the underlying pathophysiology of sickle cell anemia (SCA), exacerbating hemolysis and complicating the maternal-fetal interface. Pregnancy induces a hypercoagulable state, increases blood volume, and augments cardiac output, all of which impose additional stress on the fragile erythrocytes characteristic of SCA. These physiological alterations, combined with the inherent abnormalities in hemoglobin structure and function, contribute to the pathophysiology of hemolysis in pregnant women with SCA. During pregnancy, the expansion of blood volume leads to hemodilution and anemia, further challenging the already compromised erythrocytes in SCA. Increased erythropoietin production stimulates bone marrow erythropoiesis, resulting in the production of more sickle cells, which are prone to hemolysis under physiological stress. Moreover, the release of placental hormones, including estrogen and progesterone, alters red blood cell (RBC) rheology, promoting sickling and hemolysis in women with SCA. 46-69

The hypercoagulable state of pregnancy exacerbates the risk of vaso-occlusive events and acute complications in women with SCA. Endothelial activation and dysfunction, coupled with increased platelet aggregation and thrombin generation, contribute to microvascular thrombosis, tissue ischemia, and organ damage. The prothrombotic milieu of pregnancy further amplifies the risk of venous thromboembolism, particularly in women with SCA who already have a predisposition to thrombotic events. In addition to the physiological changes of pregnancy, pregnancy-related complications such as preeclampsia and infection can exacerbate hemolysis in women with SCA. Preeclampsia, characterized by hypertension and proteinuria, is associated with endothelial dysfunction, placental insufficiency, and oxidative stress, all of which can trigger hemolysis and vaso-occlusive crises in women with SCA. Similarly, infections during pregnancy, such as urinary tract infections and chorioamnionitis, can exacerbate hemolysis and increase the risk of maternal and fetal complications. ⁷⁰⁻⁸⁶

Complications and Management Strategies

Pregnancy in women with sickle cell anemia (SCA) is associated with an increased risk of complications, including vaso-occlusive crises, acute chest syndrome, alloimmunization, anemia, and maternal-fetal complications. Effective management strategies aim to minimize the impact of these complications on maternal and fetal health while optimizing pregnancy outcomes. Vaso-occlusive crises are a hallmark feature of SCA and can occur more frequently during pregnancy due to increased hemolytic stress. Management strategies for vaso-occlusive crises in pregnant women with SCA include hydration, analgesia, and supportive care. Intravenous fluids help maintain hydration and prevent dehydration, which can exacerbate sickling and vaso-occlusion. Analgesics such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) provide pain relief, while blood transfusions may be indicated for severe cases refractory to conservative measures.⁸⁷⁻⁹⁸

Acute Chest Syndrome (ACS) is a life-threatening complication of SCA characterized by pulmonary vaso-occlusion and respiratory symptoms. Pregnant women with SCA are at increased risk of ACS due to the hypercoagulable state of pregnancy and the increased hemolytic burden. Management of ACS in pregnancy involves supportive care, supplemental oxygen, analgesia, and close monitoring for signs of respiratory distress. Blood transfusions may be necessary to improve oxygenation and reduce the risk of complications. Alloimmunization, or the development of antibodies against foreign red blood cell antigens, can occur in pregnant women with SCA who receive multiple blood transfusions. Alloimmunization can lead to hemolytic transfusion reactions and complications such as delayed hemolytic transfusion reactions and hemolytic disease of the fetus and newborn (HDFN). Management strategies include antigen matching for blood transfusions, monitoring maternal antibody titers, and providing specialized care for affected fetuses and newborns. Anemia is a common complication of SCA during pregnancy, exacerbated by increased hemolysis and the physiological changes of gestation. Management strategies for anemia in pregnant women with SCA include iron supplementation, folic acid supplementation, Citation: Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2(3): 67-80

and blood transfusions as needed. Close monitoring of maternal hemoglobin levels and fetal growth is essential to detect and manage anemia promptly and prevent adverse pregnancy outcomes. Pregnant women with SCA are at increased risk of maternal-fetal complications, including preterm birth, intrauterine growth restriction, and maternal mortality. Management strategies aim to optimize prenatal care, monitor maternal and fetal well-being, and prevent complications through regular antenatal visits, fetal surveillance, and multidisciplinary collaboration. Close coordination between obstetricians, hematologists, and maternal-fetal medicine specialists is essential to provide comprehensive care and minimize the risk of adverse outcomes for both mother and fetus. 99-109

Challenges and Future Directions

Despite advancements in prenatal care and management, pregnant women with sickle cell anemia (SCA) continue to face numerous challenges that impact maternal and fetal health outcomes. Addressing these challenges and charting future directions in the management of pregnancy in women with SCA requires a multifaceted approach that encompasses research, clinical care, advocacy, and policy initiatives. Access to specialized care for pregnant women with SCA remains a significant challenge, particularly in resource-limited settings where healthcare infrastructure may be inadequate. Limited availability of hematologists, maternal-fetal medicine specialists, and comprehensive sickle cell centers can impede timely diagnosis, monitoring, and management of complications during pregnancy. Future efforts should focus on expanding access to specialized care through training of healthcare providers, establishment of multidisciplinary clinics, and integration of sickle cell services into existing maternal health programs. 110

Socioeconomic factors such as poverty, lack of education, and inadequate healthcare coverage contribute to disparities in pregnancy outcomes among women with SCA. Limited access to prenatal care, poor nutrition, and social stressors exacerbates the risk of complications and adverse outcomes for both mother and fetus. Addressing socioeconomic disparities requires a holistic approach that addresses social determinants of health, provides financial support for healthcare services, and promotes health literacy and empowerment among women with SCA. The lack of evidence-based guidelines for the management of pregnancy in women with SCA poses a significant challenge for healthcare providers. Clinical decision-making may be guided by expert opinion rather than robust evidence, leading to variability in practice and suboptimal outcomes. Future research should focus on generating high-quality evidence through prospective studies, clinical trials, and collaborative research networks to inform the development of evidence-based guidelines and best practices for the management of pregnancy in women with SCA.

Pregnant women with SCA face unique psychosocial challenges related to the burden of chronic illness, fear of complications, and uncertainty about pregnancy outcomes. Psychosocial support services, including counseling, peer support groups, and mental health interventions, are essential for addressing the emotional and psychological needs of women with SCA during pregnancy. **Citation**: Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. *Elite Journal of Haematology*, 2024; 2(3): 67-80

Future directions should prioritize the integration of psychosocial support services into prenatal care programs, training of healthcare providers in mental health counseling, and raising awareness about the importance of mental health in pregnancy. Advances in research and technology hold promise for improving pregnancy outcomes in women with SCA. Emerging technologies such as noninvasive prenatal testing (NIPT), fetal hemoglobin inducers, and gene editing techniques offer novel approaches for early detection of complications, prevention of hemolysis, and targeted interventions for maternal-fetal health. Collaborative research efforts, investment in innovative technologies, and translation of research findings into clinical practice are essential for advancing the field of pregnancy management in women with SCA and improving outcomes for future generations.

Conclusion

The management of pregnancy in women with sickle cell anemia (SCA) presents complex challenges that require a multifaceted approach addressing clinical, social, and psychosocial factors. Despite advancements in prenatal care and management strategies, significant disparities persist in access to specialized care, socioeconomic resources, and evidence-based guidelines. Addressing these challenges requires concerted efforts from healthcare providers, researchers, policymakers, and advocates to ensure equitable access to quality care and improve pregnancy outcomes for women with SCA and their offspring. Moving forward, it is imperative to prioritize the expansion of access to specialized care, particularly in resource-limited settings, through training of healthcare providers, establishment of multidisciplinary clinics, and integration of sickle cell services into existing maternal health programs. Additionally, efforts to address socioeconomic disparities, promote psychosocial support, and advance research and technology should be accelerated to enhance the holistic care of pregnant women with SCA.

References

- 1. Tebbi CK. Sickle cell disease, a review. Hemato. 20220;3(2):341-366.
- 2. Pecker LH, Little J. Clinical manifestations of sickle cell disease across the lifespan. Sickle cell disease and hematopoietic stem cell transplantation. 2018:3-9.
- 3. Egesa WI, Nakalema G, Waibi WM, Turyasiima M, Amuje E, Kiconco G, Odoch S, Kumbakulu PK, Abdirashid S, Asiimwe D. Sickle cell disease in children and adolescents: a review of the historical, clinical, and public health perspective of sub-saharan africa and beyond. International Journal of Pediatrics. 2022.
- 4. Fasano RM, Meier ER, Chonat S. Sickle cell disease, thalassemia, and hereditary hemolytic anemias. Rossi's Principles of Transfusion Medicine. 2022:326-345.
- 5. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
- 6. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.

- 7. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
- 8. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
- 9. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences. 2023 Sep 11;6(4):12-17.
- 10. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
- 11. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-8.
- 12. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-0487.
- 13. Obeagu EI, Obeagu GU, Igwe MC, Alum EU, Ugwu OP. Men's Essential roles in the Management of Sickle Cell Anemia. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 4(2):20-29. https://doi.org/10.59298/NIJSES/2023/10.3.1111
- 14. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
- 15. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research. 2023;6(1):2768-0487.
- 16. Obeagu EI, Agreen FC. Anaemia among pregnant women: A review of African pregnant teenagers. J Pub Health Nutri. 2023; 6 (1). 2023;138. links/63da799664fc860638054562/Anaemia-among-pregnant-women-A-review-of-African-pregnant-teenagers.pdf.
- 17. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-8. links/5710fae108ae846f4ef05afb/ERYTHROPOIETIN-IN-THE-ANAEMIAS-OF-PREGNANCY-A-REVIEW.pdf.
- 18. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021 Apr;9(4):145-8. links/608a6728a6fdccaebdf52d94/Assessment-of-Haematological-Changes-in-Pregnant-Women-of-Ido-Ondo.pdf.
- 19. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-3. http://irmhs.com/index.php/irmhs/article/view/111.
- 20. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis,

- Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. https://links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
- 21. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of Protein C, Protein S and Fibrinogen of Pregnant Women with Malaria in Owerri Metropolis. Madonna University journal of Medicine and Health Sciences. 2022;2(2):1-9.
- 22. Obeagu EI, Ikpenwa JN, Chukwueze CM, Obeagu GU. Evaluation of protein C, protein S and fibrinogen of pregnant women in Owerri Metropolis. Madonna University Journal of Medicine and Health Sciences. 2022;2(1):292-8. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/57.
- 23. Obeagu EI, Obeagu GU, Adepoju OJ. Evaluation of haematological parameters of pregnant women based on age groups in Olorunsogo road area of Ido, Ondo state. J. Bio. Innov11 (3). 2022:936-41.
- 24. Obeagu EI. An update on utilization of antenatal care among pregnant Women in Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2022;9(9):21-6.DOI: 10.22192/ijcrcps.2022.09.09.003
- 25. Okoroiwu IL, Obeagu EI, Obeagu GU. Determination of clot retraction in preganant women attending antenatal clinic in federal medical centre Owerri, Nigeria. Madonna University Journal of Medicine and Health Sciences. 2022;2(2):91-7. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/67.
- 26. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
- 27. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine. 2023;102(48):e36462.
- 28. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
- 29. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
- 30. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU. Anaemia in children under five years: African perspectives. Int. J. Curr. Res. Biol. Med. 2023;1:1-7.
- 31. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
- 32. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
- 33. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
- 34. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluation of Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.

- 35. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
- 36. Obeagu EI, Hassan AO, Adepoju OJ, Obeagu GU, Okafor CJ. Evaluation of Changes in Haematological Parameters of Pregnant Women Based on Gestational Age at Olorunsogo Road Area of Ido, Ondo State. Nigeria. Journal of Research in Medical and Dental Science. 2021;9(12):462-.links/61b1e32f0c4bfb675178bfa7/Evaluation-of-Changes-in-Haematological-Parameters-of-Pregnant-Women-Based-on-Gestational-Age-at-Olorunsogo-Road-Area-of-Ido-Ondo-State-Nigeria.pdf.
- 37. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Irondi EA, Arinze-Anyiam OC, Asiyah MK. ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. International Journal of Research and Reports in Hematology. 2022 Jun 21;5(2):113-121.
- 38. Obeagu EI. Gestational Thrombocytopaenia. J Gynecol Women's Health. 2023;25(3):556163. links/64b01aa88de7ed28ba95fccb/Gestational-Thrombocytopaenia.pdf.
- 39. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022 Aug 9;13(2):26-31.
- 40. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021 Feb 23;33(4):10-9
- 41. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3):134-43.DOI: 10.22192/ijarbs.2023.10.03.016
- 42. Obeagu EI, Ogunnaya FU. PREGNANCYINDUCED HAEMATOLOGICAL CHANGES: A KEY TO MARTERNAL AND CHILD HEALTH. European Journal of Biomedical. 2023;10(8):42-3. links/64c890bddb38b20d6dad2c5c/PREGNANCY-INDUCED-HAEMATOLOGICAL-CHANGES-A-KEY-TO-MARTERNAL-AND-CHILD-HEALTH.pdf.
- 43. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-9.
- 44. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research. 2017;5(4):206. links/5ea97df145851592d6a8acf2/Iron-Status-

- <u>of-Pregnant-and-Post-Partum-Women-with-Malaria-Parasitaemia-in-Aba-Abia-State-Nigeria.pdf.</u>
- 45. Eze RI, Obeagu EI, Edet FN. Frequency of Rh Antigen C And c among pregnant women in Sub-Urban area in Eastern Nigeria. Madonna Uni J Med Health Sci. 2021;1(1):19-30.
- 46. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
- 47. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
- 48. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
- 49. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-5.
- 50. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
- 51. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
- 52. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
- 53. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO. Sickle Cell Anaemia: Current Burden in Africa. International Journal of Innovative and Applied Research. 2023;11(2):12-14.
- 54. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10; 6 (2): 10-13.
- 55. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
- 56. Obeagu EI, Ofodile AC, Okwuanaso CB. A review of urinary tract infections in pregnant women: Risks factors. J Pub Health Nutri. 2023; 6 (1). 2023;137:26-35. links/63c3a9116fe15d6a571e8bba/A-review-of-urinary-tract-infections-in-pregnant-women-Risks-factors.pdf.
- 57. Obeagu EI, Obeagu GU, Musiimenta E. Post partum haemorrhage among pregnant women: Update on risks factors. Int. J. Curr. Res. Med. Sci. 2023;9(2):14-7.DOI: 10.22192/ijcrms.2023.09.02.003

- 58. Obeagu EI, Obeagu GU, Ogunnaya FU. Deep vein thrombosis in pregnancy: A review of prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8):14-21.DOI: 10.22192/ijcrcps.2023.10.08.002
- 59. Jakheng SP, Obeagu EI, Jakheng EW, Uwakwe OS, Eze GC, Obeagu GU, Vidya S, Kumar S. Occurrence of Chlamydial Infection Based on Clinical Symptoms and Clinical History among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. International Journal of Research and Reports in Gynaecology. 2022;5(3):98-105.
- 60. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of some haematological parameters in malaria infected pregnant women in Imo state Nigeria. Int. J. Curr. Res. Biol. Med. 2018;3(9):1-4.DOI: 10.22192/ijcrbm.2018.03.09.001
- 61. Onyenweaku FC, Amah HC, Obeagu EI, Nwandikor UU, Onwuasoanya UF. Prevalence of asymptomatic bacteriuria and its antibiotic susceptibility pattern in pregnant women attending private ante natal clinics in Umuahia Metropolitan. Int J Curr Res Biol Med. 2017;2(2):13-23.DOI: 10.22192/ijcrbm.2017.02.02.003
- 62. Okoroiwu IL, Chinedu-Madu JU, Obeagu EI, Vincent CC, Ochiabuto OM, Ibekwe AM, Amaechi CO, Agu CC, Anoh NV, Amadi NM. Evaluation of Iron Status, Haemoglobin and Protein Levels of Pregnant Women in Owerri Metropolis. Journal of Pharmaceutical Research International. 2021 Apr 29;33(27A):36-43.
- 63. Obeagu EI, Njar VE, Obeagu GU. Infertility: Prevalence and Consequences. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(7):43-50.
- 64. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. Journal of Pharmaceutical Research International. 2021 Aug 25;33(42A):53-65.
- 65. Obeagu EI, Faduma MH, Uzoma G. Ectopic Pregnancy: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):40-4.DOI: 10.22192/ijcrcps.2023.10.04.004
- 66. Obeagu EI, Gamade SM, Obeagu GU. The roles of Neutrophils in pregnancy. Int. J. Curr. Res. Med. Sci. 2023;9(5):31-5.DOI: 10.22192/ijcrms.2023.09.05.005
- 67. Eze R, Obeagu EI, Nwakulite A, Okoroiwu IL, Vincent CC, Okafor CJ, Chukwurah EF, Chijioke UO, Amaechi CO. Evaluation of Copper Status and Some Red Cell Parameters of Pregnant Women in Enugu State, South Eastern Nigeria. Journal of Pharmaceutical Research International. 2021 May 29;33(30A):67-71.
- 68. Obeagu EI, Obeagu GU. Molar Pregnancy: Update of prevalence and risk factors. Int. J. Curr. Res. Med. Sci. 2023;9(7):25-8.DOI: 10.22192/ijcrms.2023.09.07.005
- 69. Obeagu EI, Bunu UO. Factors that influence unmet need for family planning. International Journal of Current Research in Biology and Medicine. 2023;8(1):23-7.
- 70. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
- 71. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3):134-143.

- 72. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
- 73. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
- 74. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
- 75. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
- 76. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
- 77. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Barriers to utilization of maternal health services in southern senatorial district of Cross Rivers state, Nigeria. International Journal of Advanced Multidisciplinary Research. 2017;4(8):1-9.DOI: 10.22192/ijamr.2017.04.08.001
- 78. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-11. http://research.sdpublishers.net/id/eprint/2819/.
- 79. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of coagulation parameters in malaria infected pregnant women in Imo state, Nigeria. International Journal of Current Research in Medical Sciences. 2018;4(9):41-9.DOI: 10.22192/ijcrms.2018.04.09.006
- 80. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8):22-6.DOI: 10.22192/ijcrcps.2023.10.08.003
- 81. Obeagu E, Eze RI, Obeagu EI, Nnatuanya IN, Dara EC. ZINC LEVEL IN APPARENTLY PREGNANT WOMEN IN URBAN AREA. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 2;2(1):134-48. https://www.journal.madonnauniversity.edu.ng/index.php/medicine/article/view/40.
- 82. Ogomaka IA, Obeagu EI. Malaria in Pregnancy Amidst Possession of Insecticide Treated Bed Nets (ITNs) in Orlu LGA of Imo State, Nigeria. Journal of Pharmaceutical Research International. 2021 Aug 25;33(41B):380-6.
- 83. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. SICKLE CELL ANAEMIA: A GESTATIONAL ENIGMA. migration. 2023;17:18.

- 84. Ifeanyi OE, Uzoma OG. A review on erythropietin in pregnancy. J. Gynecol. Womens Health.

 2018;8(3):1-4.

 https://www.academia.edu/download/56538560/A Review on Erythropietin in Pregnancy.pdf.
- 85. Ifeanyi OE. A review on pregnancy and haematology. Int. J. Curr. Res. Biol. Med. 2018;3(5):26-8.DOI: 10.22192/ijcrbm.2018.03.05.006
- 86. Nwosu DC, Nwanjo HU, Obeagu EI, Ibebuike JE, Ezeama MC. Ihekireh. Changes in liver enzymes and lipid profile of pregnant women with malaria in Owerri, Nigeria. International Journal of Current Research and Academic Review. 2015;3(5):376-83.
- 87. Ganesh B, Rajakumar T, Acharya SK, Kaur H. Sickle cell anemia/sickle cell disease and pregnancy outcomes among ethnic tribes in India: an integrative mini-review. The Journal of Maternal-Fetal & Neonatal Medicine. 2022;35(25):4897-4904.
- 88. Ribeil, J.A., Labopin, M., Stanislas, A., Deloison, B., Lemercier, D., Habibi, A., Albinni, S., Charlier, C., Lortholary, O., Lefrere, F. and De Montalembert, M., 2018. Transfusion-related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: A retrospective survey by the international sickle cell disease observatory. *American Journal of Hematology*, 93(6), pp.794-802.
- 89. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Factors that influence women's utilization of primary health care services in Calabar Cros river state, Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2017;4(7):28-33.
- 90. Eze R, Ezeah GA, Obeagu EI, Omeje C, Nwakulite A. Evaluation of iron status and some haematological parameters of pregnant women in Enugu, South Eastern Nigeria. World Journal of Pharmaceutical and Medical Research. 2021;7(5):251-4.
- 91. Elemchukwu Q, Obeagu EI, Ochei KC. Prevalence of Anaemia among Pregnant Women in Braithwaite Memorial Specialist Hospital (BMSH) Port Harcourt. IOSR Journal of Pharmacy and Biological Sciences. 2014;9(5):59-64.
- 92. Akandinda M, Obeagu EI, Katonera MT. Non Governmental Organizations and Women's Health Empowerment in Uganda: A Review. Asian Research Journal of Gynaecology and Obstetrics. 2022 Dec 14;8(3):12-6.
- 93. Vidya S. Sunil Kumar Shango Patience Emmanuel Jakheng, Emmanuel Ifeanyi Obeagu, Emmanuel William Jakheng, Onyekachi Splendid Uwakwe, Gloria Chizoba Eze, and Getrude Uzoma Obeagu (2022). Occurrence of Chlamydial Infection Based on Clinical Symptoms and Clinical History among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. International Journal of Research and Reports in Gynaecology.;5(3):98-105.
- 94. Gamde MS, Obeagu EI. IRON DEFICIENCY ANAEMIA: ENEMICAL TO PREGNANCY. European Journal of Biomedical. 2023;10(9):272-5. https://links/64f63358827074313ffaae7b/IRON-DEFICIENCY-ANAEMIA-ENEMICAL-TO-PREGNANCY.pdf.

- 95. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. Journal of Pharmaceutical Research International. 2021 Aug 25;33(42A):53-65.
- 96. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Studies of Some Haemostatic Variables in Preeclamptic Women in Owerri, Imo State, Nigeria. Journal of Pharmaceutical Research International. 2021 Aug 30;33(42B):39-48.
- 97. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8):22-6.
- 98. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-3.
- 99. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine. 2024;103(6):e37127.
- 100. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
- 101. Obeagu EI, Obeagu GU. Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sickle Cell Disease Education. Elite Journal of Health Science. 2024;2(2):7-15.
- 102. Obeagu EI, Obeagu GU. Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sickle Cell Disease Education. Elite Journal of Health Science. 2024;2(2):7-15.
- 103. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine. 2024 Jan 12;103(2):e36898.
- 104. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.
- 105. Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science. 2024;2(2):1-9.
- 106. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www.journalijiar.com.;12(01).
- 107. Obeagu EI, Obeagu GU. Synergistic Care Approaches: Integrating Diabetes and Sickle Cell Anemia Management. Elite Journal of Scientific Research and Review. 2024;2(1):51-64.
- 108. Obeagu EI, Obeagu GU. Improving Outcomes: Integrated Strategies for Diabetes and Sickle Cell Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):20-9.
- 109. Obeagu EI, Obeagu GU. The Role of Parents: Strengthening Adolescent Education for Sickle Cell Disease Prevention. Elite Journal of Public Health. 2024;2(1):15-21.
- 110. Munung NS, Kamga KK, Treadwell MJ, Dennis-Antwi J, Anie KA, Bukini D, Makani J, Wonkam A. Perceptions and preferences for genetic testing for sickle cell Citation: Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. *Elite Journal of Haematology*, 2024; 2(3): 67-80

Elite Journal of Haematology. Volume 2 issue 3(2024), Pp. 67-80 https://epjournals.com/journals/EJH

disease or trait: a qualitative study in Cameroon, Ghana and Tanzania. European Journal of Human Genetics. 2024:1-7.

111. Arthur MN, DeLong RN, Kucera K, Goettsch BP, Schattenkerk J, Bekker S, Drezner JA. Socioeconomic deprivation and racialised disparities in competitive athletes with sudden cardiac arrest from the USA. British Journal of Sports Medicine. 2024.